BioSpace News Archive

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023 in Boston, MA.

Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2023 after the market close on Thursday, August 3, 2023.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023.

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced results for the three months ended June 30, 2023.

Telavant, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics to help patients living with inflammatory and fibrotic diseases, announced today the initiation of the TAHOE study, a Phase 2 clinical trial of RVT-3101 for the treatment of moderate to severely active CD, with first patient dosed.

Synthekine Inc. today announced that the first patient has been dosed in a Phase 1 clinical trial of its orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, in adults with relapsed or refractory CD19+ hematologic malignancies.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023.

Avenue Therapeutics, Inc. today announced that the first patient has been dosed in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease.

Glyscend Therapeutics today announced that safety and pharmacodynamic data from the first-in-human Phase 1 trial of GLY-200 were published in Diabetes, Obesity and Metabolism.